Because the development of CML is a direct result of the fusion protein transcribed from BCR::ABL1, miRNAs which directly target these transcripts before they can be translated into the oncoprotein are obvious therapeutic candidates and were the focus of early studies of non-coding RNAs in CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.